Determination of microsatellite instability, p53 and K-ras mutations in hepatic metastases from patients with colorectal cancer: Relationship with response to 5-fluorouracil and survival

International Journal of Cancer

Volumn 95, Issue 3, 2001, Pages 162-167

  Rosty, Christophe ^a   Chazal, Maurice ^c,f   Etienne, Marie Christine ^c   Letoublon, Christian ^e   Bourgeon, André ^f   Delpero, Jean Robert ^g   Pezet, Denis ^h   Beaune, Philippe ^b   Laurent Puig, Pierre ^b,d   Milano, Gérard ^c  

^a INSERM   (France)

^b Centre Antoine Lacassagne ^*

^c CENTRE ANTOINE LACASSAGNE   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e HÔPITAL MICHALLON   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h HÔTEL DIEU   (France)

Author keywords

Chemotherapy; Colorectal cancer; Hepatic metastasis; K ras; Microsatellite instability; p53; Prognosis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG INDICATION; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENES, RAS; HUMANS; LIVER NEOPLASMS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035918589     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010520)95:3<162::AID-IJC1028>3.0.CO;2-J     Document Type: Article

References (58)

1. Roncucci L, Fante R, Losi L, Di Gregorio C, Micheli A, Benatti P, et al. Survival for colon and rectal cancer in a population-based cancer registry. Eur J Cancer 1996;32A:295-302.
2. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995;13:1303-11.
3. Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7: 1419-26.
4. Rougier P, Lasser P, Elias D. Chimiothérapie des métastases hépatiques d'origine colorectale. In: Norlinger B, Jack N. Traitement des métastases hépatiques des cancers colorectaux. Paris: Springer-Verlag, 1992:119-40.
5. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994;330:1136-42.
6. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-32.
7. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-18.
8. Geoffroy FJ, Allegra CJ, Sinha B, Grem JL. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells. Oncol Res 1994;6:581-91.
9. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990;48:381-95.
10. Weckbecker G. Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators. Pharmacol Ther 1991:50:367-424.
11. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998; 16:2739-44.
12. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-60.
13. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-12.
14. Peters GJ, Van Der Wilt CL, Van Triest B, Codacci-Pisanelli G, Johnston PG, Van Groeningen CJ, et al. Thymidylate synthase and drug resistance. Eur J Cancer 1995;31A:1299-305.
15. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57-64.
16. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
17. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55:5217-21.
18. Hailing KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999;91:1295-303.
19. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8.
20. Tortola S, Marcuello E, Gonzalez I, Reyes G, Arribas R, Aiza G, et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999;17:1375-81.
21. Lowe SW. Cancer therapy and p53. Curr Opin Oncol 1995;7:547-53.
22. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-9.
23. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998;292:435-45.
24. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
25. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6.
26. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999;117:123-31.
27. Hamelin R, Jego N, Laurent-Puig P, Vidaud M, Thomas G. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene 1993;8:2213-2220.
28. Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J. Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat 1997;9:348-55.
29. Iacopetta BJ, Soong R, House AK, Hamelin R. Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes. J Pathol 1999;187:428-32.
30. Zhou XP, Hoang JM, Li YJ, Seruca R, Cameiro F, Sobrinho-Simoes M, et al. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer 1998;21:101-7.
31. Losi L, Ponz De Leon M, Jiricny J, Di Gregorio C, Benatti P, Percesepe A, et al. K-ras and p53 mutations in hereditary nonpolyposis colorectal cancers. Int J Cancer 1997;74:94-6.
32. Heide I, Thiede C, Sonntag T, De Kant E, Neubauer A, Jonas S, et al. The status of p53 in the metastatic progression of colorectal cancer. Eur J Cancer 1997;33:1314-22.
33. Kastrinakis WV, Ramchurren N, Rieger KM, Hess DT, Loda M, Steele G, et al. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 1995;11:647-52.
34. Yao J, Goh HS, Smith DR, p53 mutations in primary colorectal adenocarcinomas and liver metastases. Br J Surg 1996;83:1245-6.
35. Bertorelle R, Esposito G, Del Mistro A, Belluco C, Nitti D, Use M, et al. Association of p53 gene and protein alterations with metastases in colorectal cancer. Am J Surg Pathol 1995;19:463-71.
36. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998;58:1149-58.
37. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 1998;4:1243-50.
38. Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas, Int J Cancer 1996;69:190-2.
39. Borresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 1998;4:203-10.
40. Mulder JW, Baas IO, Polak MM, Goodman SN, Offerhaus GJ. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 1995;71:1257-62.
41. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 1991;63:317-9.
42. Slebos RJ, Baas IO, Clement M, Polak M, Mulder JW, Van Den Berg FM, et al. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br J Cancer 1996;74:165-71.
43. Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999;17:1364-74.
44. Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T, et al. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992;340:1369-73.
45. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
46. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:95-67.
47. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999;18:477-85.
48. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
49. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-9.
50. Nemunaitis J, Cox J, Meyer W, Courtney A, Mues G. Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU). Am J Clin Oncol 1997;20:527-9.
51. Markowitz S, Hines JD, Lutterbaugh J, Myeroff L, Mackay W, Gordon N, et al. Mutant K-ras oncogenes in colon cancers do not predict patient's chemotherapy response or survival. Clin Cancer Res 1995;1:441-5.
52. Wadler S, Bajaj R, Neuberg D, Agarwal V, Haynes H, Benson AB III. Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the Eastern Cooperative Oncology Group (EST 2292). Cancer J Sci Am 1997;3:284-8.
53. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248-57.
54. Gonzalez-Garcia I, Moreno V, Navarro M, Marti-Rague J, Marcuello E, Benasco C, et al. Standardized approach for microsatellite instability detection in colorectal carcinomas. J Natl Cancer Inst 2000;92: 544-9.
55. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
56. Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000;119:921-8.
57. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996;110:682-7.
58. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993;53:5849-52.